BMS Joins Other Pharma Investing in Biacore®C for QC
BMS Joins Other Pharma Investing in Biacore®C for QC Uppsala, Sweden, 7th August, 2002 Biacore International AB today announced that Bristol-Myers Squibb (BMS) is the latest major pharmaceutical company to invest in its Biacore©C system for rapid concentration analysis in drug development, manufacturing quality control (QC) and in-process control applications. Biacore C is the first system based on Surface Plasmon Resonance technology designed specifically for compliance with worldwide regulatory requirements. Offering the combined benefits of real-time data analysis with state-of- the-art